Search Result

Results for "

hyperglycemic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (4) AMPK (3) Amylases (2) Amyloid-β (3) Androgen Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (2) Arginase (3) Bacterial (1) Biochemical Assay Reagents (1) Cholinesterase (ChE) (1) COX (2) Dipeptidyl Peptidase (1) Drug Metabolite (1) Endogenous Metabolite (6) Estrogen Receptor/ERR (2) Free Fatty Acid Receptor (1) GLP Receptor (1) Glucokinase (2) GLUT (1) Glycosidase (8) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (1) Histone Acetyltransferase (1) IKK (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) MMP (1) MOFs (2) mTOR (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) PARP (1) PEPCK (1) Phosphodiesterase (PDE) (2) PKC (1) PPAR (3) Reactive Oxygen Species (ROS) (1) Reference Standards (8) SGLT (2) Sirtuin (1) TNF Receptor (6) Topoisomerase (1) β-catenin (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (7) Endocrinology (7) Infection (4) Inflammation/Immunology (9) Metabolic Disease (35) Neurological Disease (7)

By Targets:

Adrenergic Receptor (4)

AMPK (3)

Amylases (2)

Amyloid-β (3)

Androgen Receptor (2)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (2)

Arginase (3)

Bacterial (1)

Biochemical Assay Reagents (1)

Cholinesterase (ChE) (1)

COX (2)

Dipeptidyl Peptidase (1)

Drug Metabolite (1)

Endogenous Metabolite (6)

Estrogen Receptor/ERR (2)

Free Fatty Acid Receptor (1)

GLP Receptor (1)

Glucokinase (2)

GLUT (1)

Glycosidase (8)

HIF/HIF Prolyl-Hydroxylase (1)

Histamine Receptor (1)

Histone Acetyltransferase (1)

IKK (1)

Insulin Receptor (1)

Isotope-Labeled Compounds (1)

MMP (1)

MOFs (2)

mTOR (1)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (1)

PARP (1)

PEPCK (1)

Phosphodiesterase (PDE) (2)

PKC (1)

PPAR (3)

Reactive Oxygen Species (ROS) (1)

Reference Standards (8)

SGLT (2)

Sirtuin (1)

TNF Receptor (6)

Topoisomerase (1)

β-catenin (1)

By Research Areas:

Cancer (8)

Cardiovascular Disease (7)

Endocrinology (7)

Infection (4)

Inflammation/Immunology (9)

Metabolic Disease (35)

Neurological Disease (7)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D0020

2,2'-Bipyridine 1 Publications Verification	MOFs	Infection Endocrinology
2,2'-Bipyridine is the unique molecular scaffold of the bioactive natural products. 2,2'-Bipyridine is extensively used as the core structure of many chelating ligands by acting as a bridge in the arrangement of the catalytic center. 2,2'-Bipyridine shows robust redox stability and hyperglycemic activity .

HY-N0547

Nomilin 2 Publications Verification	Others	Metabolic Disease
Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .

HY-B0225

Methyldopa 2 Publications Verification L-(-)-α-Methyldopa; MK-351	Adrenergic Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Methyldopa (L-(-)-α-Methyldopa), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system .

HY-N0472

Geraniin 3 Publications Verification	TNF Receptor	Metabolic Disease Inflammation/Immunology Cancer
Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC₅₀ of 43 μM.

HY-107394

UK 356618 Maximum Cited Publications 6 Publications Verification	MMP	Inflammation/Immunology Cancer
UK 356618 (Compound 4j) is a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) with an IC₅₀ of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with MMP-3 .

HY-B0225B

Methyldopa hydrate 2 Publications Verification L-(-)-α-Methyldopa hydrate; MK-351 hydrate	Adrenergic Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Methyldopa hydrate (L-(-)-α-Methyldopa hydrate), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrate is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system .

HY-Y0399

L-Norvaline Norvaline	Amyloid-β TNF Receptor Arginase	Neurological Disease Metabolic Disease
L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .

HY-N1390

Syringaldehyde 4 Publications Verification	COX	Metabolic Disease Inflammation/Immunology
Syringaldehyde is a polyphenolic compound belonging to the group of flavonoids and is found in different plant species like Manihot esculenta and Magnolia officinalis . Syringaldehyde moderately inhibits COX-2 activity with an IC₅₀ of 3.5 μg/mL . Anti-hyperglycemic and anti-inflammatory activities .

HY-120380

FeTMPyP	MOFs PARP	Neurological Disease
FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. FeTMPyP inhibits cell death, nitrotyrosine formation, and depolarization of mitochondrial transmembrane potential. FeTMPyP reduces homocysteine-induced nitrosative stress and partially restores TFEB protein and mRNA levels. FeTMPyP improves functional and behavioral deficits caused by chronic constriction injury in rats. FeTMPyP alleviates acute cerebral infarction in a rat model of middle cerebral artery occlusion with mild hyperglycemia. FeTMPyP can be used in studies related to neuropathic pain, renal aging, ischemic penumbra, and hyperglycemic stroke .

HY-N6660

Trisdecanoin Tricaprin; Glyceryl tridecanoate	Endogenous Metabolite Androgen Receptor	Cardiovascular Disease Metabolic Disease
Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics .

HY-W011220

Ciglitazone 1 Publications Verification ADD-3878; U-63287	PPAR	Cardiovascular Disease Cancer
Ciglitazone is a potent and selective PPARγ agonist (EC₅₀=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells .

HY-N2168

Pinoresinol 4-O-β-D-glucopyranoside 1 Publications Verification (+)-Pinoresinol 4-O-β-D-glucopyranoside	Glycosidase Estrogen Receptor/ERR Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Cancer
Pinoresinol 4-O-β-D-glucopyranoside ((+)-Pinoresinol 4-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor, with an IC₅₀ of 48.13 μg/mL. Pinoresinol 4-O-β-D-glucopyranoside binds to estrogen receptors. Pinoresinol 4-O-β-D-glucopyranoside inhibits phosphodiesterase. Pinoresinol 4-O-β-D-glucopyranoside exhibits various activities such as antioxidant, anti-inflammatory, anti-hyperglycemic, hepatoprotective and anti-epileptic effects .

HY-131334

AMPK activator 4	AMPK	Metabolic Disease
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .

HY-110118

Edaglitazone	PPAR	Metabolic Disease
Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC₅₀s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .

HY-133127

AR453588	Glucokinase	Metabolic Disease
AR453588 is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC₅₀ of 42 nM. AR453588 shows anti-hyperglycemic activity .

HY-N1185

Tagitinin A	Others	Metabolic Disease
Tagitinin A is a sesquiterpene with anti-hyperglycemic activity. Tagitinin A significantly inhibits glucose uptake in differentiated 3T3-L1 adipocytes .

HY-146128

*Anti-hyperglycemic* agent-1**	Glycosidase	Metabolic Disease
Anti-hyperglycemic agent-1 (compound 10) is a potent α-Glucosidase inhibitor, with an IC₅₀ of 0.53 μM. Anti-hyperglycemic agent-1 can be used for diabetes research .

HY-W197205

SL010110	Sirtuin Histone Acetyltransferase PEPCK	Metabolic Disease
SL010110 is an anti-hyperglycemic agent. SL010110 potently inhibits gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 degradation. SL010110 downregulates the protein level of PEPCK1 without affecting the gene expressions of PEPCK, glucose-6-phosphatase, and fructose-1,6-bisphosphatase. SL010110 significantly improves glucose homeostasis in type 2 diabetic (T2D) mice model. SL010110 can be used for T2D research .

HY-B0225A

Methyldopa hydrochloride L-(-)-α-Methyldopa hydrochloride; MK-351 hydrochloride	Adrenergic Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Methyldopa hydrochloride (L-(-)-α-Methyldopa hydrochloride) hydrochloride, a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrochloride is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system .

HY-Y0399S

L-Norvaline-d5	Isotope-Labeled Compounds Amyloid-β TNF Receptor Arginase	Neurological Disease Metabolic Disease
L-Norvaline-d₅ is the deuterium labeled L-Norvaline. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .

HY-Y0399R

L-Norvaline (Standard)	Amyloid-β Reference Standards TNF Receptor Arginase	Neurological Disease Metabolic Disease
L-Norvaline (Standard) is the analytical standard of L-Norvaline (HY-Y0399). This product is intended for research and analytical applications. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .

HY-N3078

p-Hydroxyphenethyl trans-ferulate	Glycosidase	Endocrinology Cancer
p-Hydroxyphenethyl trans-ferulate has anti-hyperglycemic (yeast α-glucosidase, IC₅₀=19.24 ± 1.73 µM), antioxidant, and anti-inflammatory activities . p-Hydroxyphenethyl trans-ferulate shows inhibiting anticancer and serotonergic activity .

HY-178935

α-Amylase-IN-14	Amylases Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
α-Amylase-IN-14, a derivative of Nicotinic (HY-B0143), is an α-amylase inhibitor and has good interactions with α-amylase protein (-5.55 kcal/mol). α-Amylase-IN-14 is a dual anti-inflammatory and anti-hyperglycemic agent. α-Amylase-IN-14 exhibits good results against DPPH and ABTS radicals. α-Amylase-IN-14 can be used for the study of diabetes .

HY-D0020R

2,2'-Bipyridine (Standard)	Biochemical Assay Reagents Reference Standards	Infection Endocrinology
2,2'-Bipyridine (Standard) is the analytical standard of 2,2'-Bipyridine. This product is intended for research and analytical applications. 2,2'-Bipyridine is the unique molecular scaffold of the bioactive natural products. 2,2'-Bipyridine is extensively used as the core structure of many chelating ligands by acting as a bridge in the arrangement of the catalytic center. 2,2'-Bipyridine shows robust redox stability and hyperglycemic activity .

HY-168989

Olorigliflozin	SGLT	Metabolic Disease
Olorigliflozin is a sodium glucose co-transporter inhibitor with anti-hyperglycemic effects .

HY-170943

Antidiabetic agent 7	AMPK GLUT	Metabolic Disease
Antidiabetic agent 7 (Compound 5m) is hyperglycemic inhibitor. Antidiabetic agent 7 exhibits promising potency to stimulate GLUT4 translocation in skeletal muscle cells via activating AMPK-dependent pathway. Antidiabetic agent 7 reduces blood glucose levels. Antidiabetic agent 7 shows favorable pharmacokinetic properties. Antidiabetic agent 7 is potential to be used for anti-hyperglycemic research .

HY-133127A

AR453588 hydrochloride	Glucokinase	Metabolic Disease
AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC₅₀ of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity .

HY-B0225BR

Methyldopa hydrate (Standard) L-(-)-α-Methyldopa hydrate (Standard); MK-351 hydrate (Standard)	Reference Standards Adrenergic Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Methyldopa (hydrate) (Standard) is the analytical standard of Methyldopa (hydrate). This product is intended for research and analytical applications. Methyldopa hydrate (L-(-)-α-Methyldopa hydrate), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrate is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system .

HY-N8018

Leucosceptoside A	PKC Glycosidase Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Neurological Disease Metabolic Disease
Leucosceptoside A is a phenylethanoid glycoside with anti-hyperglycemic and anti-hypertensive activities. Leucosceptoside A shows inhibitory activity against α-glucosidase and PKCα (IC₅₀ of 19.0 μM) .

HY-N0547R

Nomilin (Standard)	Apoptosis IKK TNF Receptor Reference Standards	Metabolic Disease
Nomilin (Standard) is the analytical standard of Nomilin. This product is intended for research and analytical applications. Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .

HY-N0472R

Geraniin (Standard)	Reference Standards TNF Receptor	Metabolic Disease Inflammation/Immunology Cancer
Geraniin (Standard) is the analytical standard of Geraniin. This product is intended for research and analytical applications. Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC₅₀ of 43 μM.

HY-19176

S-15261	Insulin Receptor	Metabolic Disease
S-15261 is an orally active and potent anti-hyperglycemic agent. S-15261 reduces hepatic glucose production through direct and insulin-sensitizing effects. S-15261 can be used for the research of insulin resistance syndrome .

HY-N13082

Deacetylescin Ia	Others	Metabolic Disease
Deacetylescin Ia (compound 12) is a deacetylated compound with anti-hyperglycemic effects that can be extracted from the debittered Aesculus and deacetylated at the C-22 position. Deacetylescin Ia (100 mg/kg) can inhibit blood glucose elevation in mouse glucose tolerance tests .

HY-167640

8-Hydroxychlorpromazine	Drug Metabolite	Metabolic Disease
8-Hydroxychlorpromazine is a metabolite of Chlorpromazine (HY-12708) that can enhance the hyperglycemic response following a glucose load, suggesting its potential synergistic role in Chlorpromazine-induced glucose metabolism disorders. 8-Hydroxychlorpromazine may be useful for research in metabolic diseases .

HY-169821

SGLT1/2-IN-8	SGLT	Metabolic Disease
SGLT1/2-IN-8 (compound 8) is a potent and orally active SGLT1/2 dual inhibitor with IC₅₀ values of 4 nM and 1 nM, respectively. SGLT1/2-IN-8 exhibits anti-hyperglycemic effects and can be utilized in relevant research .

HY-156380

α-Amylase/α-Glucosidase-IN-6	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC₅₀s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .

HY-168719

PPARγ agonist 16	PPAR	Inflammation/Immunology
PPARγ agonist 16 (Compound 4G) is the agonist for PPARγ, that competitively binds to LBD domain of PPARγ with IC₅₀ of 1790 nM. PPARγ agonist 16 inhibits the ear swelling in mouse model, and exhibits anti-hyperglycemic in Streptozotocin (HY-13753)-induced mouse diabetes mellitus model .

HY-N1390R

Syringaldehyde (Standard)	Reference Standards COX	Metabolic Disease Inflammation/Immunology
Syringaldehyde (Standard) is the analytical standard of Syringaldehyde. This product is intended for research and analytical applications. Syringaldehyde is a polyphenolic compound belonging to the group of flavonoids and is found in different plant species like Manihot esculenta and Magnolia officinalis . Syringaldehyde moderately inhibits COX-2 activity with an IC₅₀ of 3.5 μg/mL . Anti-hyperglycemic and anti-inflammatory activities .

HY-10289

Carmegliptin RO-4876904	Dipeptidyl Peptidase GLP Receptor P-glycoprotein	Metabolic Disease
Carmegliptin (RO-4876904) is an orally active and potent DPP IV inhibitor with a human DPP IV IC₅₀ of 6.8 nM. Carmegliptin binds to the S1 pocket of DPP IV, blocks the degradation of GLP 1, potentiates endogenous GLP 1, increases plasma insulin levels, alleviates hyperglycemia, improves glucose tolerance. Carmegliptin acts as a substrate for human P glycoprotein without inhibiting the transporter, shows low in vitro cell permeability. Carmegliptin can be used for the research of type 2 diabetes, non insulin dependent diabetes mellitus .

HY-N6660R

Trisdecanoin (Standard) Tricaprin (Standard); Glyceryl tridecanoate (Standard)	Reference Standards Endogenous Metabolite Androgen Receptor	Metabolic Disease
Trisdecanoin (Standard) is the analytical standard of Trisdecanoin. This product is intended for research and analytical applications. Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics .

HY-N2168R

Pinoresinol 4-O-β-D-glucopyranoside (Standard) (+)-Pinoresinol 4-O-β-D-glucopyranoside (Standard)	Glycosidase Reference Standards Estrogen Receptor/ERR Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Cancer
Pinoresinol 4-O-β-D-glucopyranoside (Standard) is the analytical standard of Pinoresinol 4-O-β-D-glucopyranoside (HY-N2168). This product is intended for research and analytical applications. Pinoresinol 4-O-β-D-glucopyranoside is an orally active α-glucosidase inhibitor, with an IC₅₀ of 48.13 μg/mL. Pinoresinol 4-O-β-D-glucopyranoside binds to estrogen receptors. Pinoresinol 4-O-β-D-glucopyranoside inhibits phosphodiesterase. Pinoresinol 4-O-β-D-glucopyranoside exhibits various activities such as antioxidant, anti-inflammatory, anti-hyperglycemic, hepatoprotective and anti-epileptic effects .

HY-N17566

Eukovoside	Bacterial Histamine Receptor	Infection Inflammation/Immunology
Eukovoside is a cinnamic acid derivative found in Euphrasia regelii with anti-inflammatory, antioxidant, antibacterial, antiallergic, and antihistamine activity. Eukovoside can be used for the research of hyperglycemic diseases, eye inflammation, upper respiratory passages inflammation, hay fever, conjunctivitis, colds, influenza, sinusitis .

HY-N17761A

Tetrandrine 2'-N-β-oxide	Others	Metabolic Disease
Tetrandrine 2'-N-β-oxide is an anti-hyperglycemic dibenzylisoquinoline alkaloid. At a dose of 1 mg/kg, Tetrandrine 2'-N-β-oxide can reduce hyperglycemia levels in streptozotocin (HY-13753)-induced diabetic mice to nearly 50% of their original levels. Tetrandrine 2'-N-β-oxide is primarily used in research related to the anti-hyperglycemic of type 2 diabetes.

HY-N9821

Giffonin P	Glycosidase	Metabolic Disease
Giffonin P is a selective inhibitor targeting α-glucosidase with an IC₅₀ of 55.3 μM. Giffonin P delays carbohydrate hydrolysis and glucose absorption, exerting anti-hyperglycemic activity. Giffonin P reduces postprandial blood glucose levels and is primarily used in research on type 2 diabetes .

HY-179729

α-Glucosidase-IN-106	Glycosidase	Metabolic Disease
α-Glucosidase-IN-106 (Compound 17F) is an inhibitor of α-glucosidase with an IC₅₀ of 14.9 μM. α-Glucosidase-IN-106 can effectively inhibit the peak of blood glucose after sucrose loading in normal mice, and shows a more significant anti-hyperglycemic effect in diabetic mice. α-Glucosidase-IN-106 can be used for research on diabetes .

HY-153667

MK-2305	Free Fatty Acid Receptor	Metabolic Disease
MK-2305 is an orally active GPR40 partial agonist with an EC₅₀ of 6 nM in rats. MK-2305 mediates glucose-stimulated insulin secretion and inhibits endogenous glucose production by reducing gluconeogenesis from tricarboxylic acid (TCA) cycle substrates. MK-2305 increases plasma insulin levels under hyperglycemic and glucose-stimulated conditions, reduces fasting blood glucose, and improves glucose homeostasis. MK-2305 can be used in studies related to type 2 diabetes .

HY-W800535

Cryptolepine	NF-κB p38 MAPK mTOR Topoisomerase AMPK Apoptosis Cholinesterase (ChE) HIF/HIF Prolyl-Hydroxylase β-catenin	Infection Metabolic Disease Inflammation/Immunology Cancer
Cryptolepine is an orally active multi-potent alkaloid with anti-cancer, anti-bacterial, anti-viral, anti-malarial, anti-inflammatory, anti-hyperglycemic, relieve pain and other properties. Cryptolepine acts as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, MAPK and an activator of AMPKα1/2. It intercalates into DNA, inhibits topoisomerase II (Top II), disrupts mitochondrial dynamics and induces apoptosis. Cryptolepine also exhibits anti-plasmodial and cholinesterase inhibitory activities. Cryptolepine can be used in research related to tumors (melanoma, hepatocellular carcinoma, mammary adenocarcinoma, etc.), malaria, inflammatory diseases and diabetes, particularly in studies focused on inhibiting tumor growth and anti-plasmodial infection .

Cat. No.	Product Name	Category	Target	Chemical Structure